US Patent Issued to ILLIMIS THERAPEUTICS on Aug. 12 for "TAM receptor-binding fusion molecule having non-inflammatory phagocytosis inducing activity" (South Korean Inventors)

ALEXANDRIA, Va., Aug. 12 -- United States Patent no. 12,384,822, issued on Aug. 12, was assigned to ILLIMIS THERAPEUTICS INC. (Seoul, South Korea).

"TAM receptor-binding fusion molecule having non-inflammatory phagocytosis inducing activity" was invented by Chan Hyuk Kim (Daejeon, South Korea), Won Suk Chung (Daejeon, South Korea), Hyun Cheol Jung (Daejeon, South Korea) and Se Young Lee (Daejeon, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "A fusion molecule having phagocytosis-inducing activity is disclosed. The fusion molecule contains a first region capable of binding a TAM receptor and a second region capable of binding to a target substance of which aberrant accumulation is associated with...